Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Indomethacin

May 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Indomethacin

Dosage Form: Suspension

Route: Oral

Strength: 25 mg/5 mL

Recommended Studies: Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 25 mg/5 mL
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 25 mg/5 mL
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

Analyte to measure: Indomethacin in plasma

Bioequivalence based on (90% CI): Indomethacin

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of the test and reference products. Note that a dosage unit for a suspension is the labeled strength (5 mL). Specifications will be determined upon evaluation of the abbreviated new drug application.

Document History: Recommended May 2024

Unique Agency Identifier: PSG_018332